Cover Image
市場調查報告書

濾胞性甲狀腺癌:開發平台分析

Follicular Thyroid Cancer - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 255938
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
濾胞性甲狀腺癌:開發平台分析 Follicular Thyroid Cancer - Pipeline Review, H1 2016
出版日期: 2016年02月24日 內容資訊: 英文 83 Pages
簡介

所謂濾胞性甲狀腺癌是最常見的甲狀腺癌。症狀有淋巴節肥大和聲音嘶啞,結節的急速肥大等。暴露於放射線中,尤其是年幼期的暴露,缺乏碘,環境暴露等是致病因素。

本報告提供濾胞性甲狀腺癌的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關最新的新聞和發表,加上開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍
  • 濾胞性甲狀腺癌 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • AstraZeneca PLC
  • Exelixis, Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • cabozantinib s-malate
  • dabrafenib mesylate
  • everolimus
  • sunitinib malate
  • tetraiodothyroacetic acid nanoparticle
  • vandetanib

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7671IDB

Summary

Global Markets Direct's, 'Follicular Thyroid Cancer - Pipeline Review, H1 2016', provides an overview of the Follicular Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Follicular Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Follicular Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Follicular Thyroid Cancer
  • The report reviews pipeline therapeutics for Follicular Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Follicular Thyroid Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Follicular Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Follicular Thyroid Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Follicular Thyroid Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Follicular Thyroid Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Follicular Thyroid Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Follicular Thyroid Cancer - Overview
  • Follicular Thyroid Cancer - Therapeutics under Development by Companies
  • Follicular Thyroid Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Follicular Thyroid Cancer - Products under Development by Companies
  • Follicular Thyroid Cancer - Companies Involved in Therapeutics Development
    • Exelixis, Inc.
    • Genzyme Corporation
    • Novartis AG
    • Pfizer Inc.
  • Follicular Thyroid Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dabrafenib mesylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pasireotide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sunitinib malate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tetraiodothyroacetic acid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vandetanib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Follicular Thyroid Cancer - Recent Pipeline Updates
  • Follicular Thyroid Cancer - Dormant Projects
  • Follicular Thyroid Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Follicular Thyroid Cancer, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Follicular Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2016
  • Follicular Thyroid Cancer - Pipeline by Genzyme Corporation, H1 2016
  • Follicular Thyroid Cancer - Pipeline by Novartis AG, H1 2016
  • Follicular Thyroid Cancer - Pipeline by Pfizer Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Follicular Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Follicular Thyroid Cancer - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Follicular Thyroid Cancer, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top